|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar
|
|
2
|
Thim L: A new family of growth factor-like
peptides. ‘Trefoil’ disulphide loop structures as a common feature
in breast cancer associated peptide (pS2), pancreatic spasmolytic
polypeptide (PSP), and frog skin peptides (spasmolysins). FEBS
Lett. 250:85–90. 1989. View Article : Google Scholar
|
|
3
|
Madsen J, Nielsen O, Tornøe I, Thim L and
Holmskov U: Tissue localization of human trefoil factors 1, 2, and
3. J Histochem Cytochem. 55:505–513. 2007. View Article : Google Scholar
|
|
4
|
Podolsky DK, Lynch-Devaney K, Stow JL,
Oates P, Murgue B, DeBeaumont M, Sands BE and Mahida YR:
Identification of human intestinal trefoil factor. Goblet
cell-specific expression of a peptide targeted for apical
secretion. J Biol Chem. 268:6694–6702. 1993.
|
|
5
|
Xiao P, Ling H, Lan G, Liu J, Hu H and
Yang R: Trefoil factors: Gastrointestinal-Specific proteins
associated with gastric cancer. Clin Chim Acta. 450:127–134. 2015.
View Article : Google Scholar
|
|
6
|
Taupin D and Podolsky DK: Trefoil factors:
Initiators of mucosal healing. Nat Rev Mol Cell Biol. 4:721–732.
2003. View
Article : Google Scholar
|
|
7
|
Hernandez C, Santamatilde E, McCreath KJ,
Cervera AM, Diez I, Ortiz-Masia D, Martínez N, Calatayud S,
Esplugues JV and Barrachina MD: Induction of trefoil factor (TFF)1,
TFF2 and TFF3 by hypoxia is mediated by hypoxia inducible factor-1:
Implications for gastric mucosal healing. Br J Pharmacol.
156:262–272. 2009. View Article : Google Scholar
|
|
8
|
Samson MH: Quantitative measurements of
trefoil factor family peptides: Possibilities and pitfalls. Scand J
Clin Lab Invest. 73:193–202. 2013. View Article : Google Scholar
|
|
9
|
Aihara E, Engevik KA and Montrose MH:
Trefoil factor peptides and gastrointestinal function. Annu Rev
Physiol. 79:357–380. 2017. View Article : Google Scholar
|
|
10
|
Wong WM, Poulsom R and Wright NA: Trefoil
peptides. Gut. 44:890–895. 1999. View Article : Google Scholar
|
|
11
|
Babyatsky M, Lin J, Yio X, Chen A, Zhang
JY, Zheng Y, Twyman C, Bao X, Schwartz M, Thung S, et al: Trefoil
factor-3 expression in human colon cancer liver metastasis. Clin
Exp Metastasis. 26:143–151. 2009. View Article : Google Scholar
|
|
12
|
Garraway IP, Seligson D, Said J, Horvath S
and Reiter RE: Trefoil factor 3 is overexpressed in human prostate
cancer. Prostate. 61:209–214. 2004. View Article : Google Scholar
|
|
13
|
Kannan N, Kang J, Kong X, Tang J, Perry
JK, Mohankumar KM, Miller LD, Liu ET, Mertani HC, Zhu T, et al:
Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance
in human mammary carcinoma. Neoplasia. 12:1041–1053. 2010.
View Article : Google Scholar
|
|
14
|
Kirikoshi H and Katoh M: Expression of
TFF1, TFF2 and TFF3 in gastric cancer. Int J Oncol. 21:655–659.
2002.
|
|
15
|
Kim WG, Kim JY and Park DY: Simple
classifiers for molecular subtypes of colorectal cancer. Arab J
Gastroenterol. 18:191–200. 2017. View Article : Google Scholar
|
|
16
|
Jahan R, Shah A, Kisling SG, Macha MA,
Thayer S, Batra SK and Kaur S: Odyssey of trefoil factors in
cancer: Diagnostic and therapeutic implications. Biochim Biophys
Acta Rev Cancer. 1873:1883622020. View Article : Google Scholar
|
|
17
|
Yusup A, Huji B, Fang C, Wang F, Dadihan
T, Wang HJ and Upur H: Expression of trefoil factors and TWIST1 in
colorectal cancer and their correlation with metastatic potential
and prognosis. World J Gastroenterol. 23:110–120. 2017. View Article : Google Scholar
|
|
18
|
Li Q, Wang K, Su C and Fang J: Serum
trefoil factor 3 as a protein biomarker for the diagnosis of
colorectal cancer. Technol Cancer Res Treat. 16:440–445. 2017.
View Article : Google Scholar
|
|
19
|
Huang YG, Li YF, Wang LP and Zhang Y:
Aberrant expression of trefoil factor 3 is associated with
colorectal carcinoma metastasis. J Cancer Res Ther. 9:376–380.
2013. View Article : Google Scholar
|
|
20
|
Chandrashekar DS, Bashel B, Balasubramanya
SA, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B and Varambally
S: UALCAN: A portal for facilitating tumor subgroup gene expression
and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar
|
|
21
|
Chen F, Chandrashekar DS, Varambally S and
Creighton CJ: Pan-Cancer molecular subtypes revealed by
mass-spectrometry-based proteomic characterization of more than 500
human cancers. Nat Commun. 10:56792019. View Article : Google Scholar
|
|
22
|
Mashimo H, Wu DC, Podolsky DK and Fishman
MC: Impaired defense of intestinal mucosa in mice lacking
intestinal trefoil factor. Science. 274:262–265. 1996. View Article : Google Scholar
|
|
23
|
Farrell JJ, Taupin D, Koh TJ, Chen D, Zhao
CM, Podolsky DK and Wang TC: TFF2/SP-deficient mice show decreased
gastric proliferation, increased acid secretion, and increased
susceptibility to NSAID injury. J Clin Invest. 1091:193–204. 2002.
View Article : Google Scholar
|
|
24
|
Carrasco R, Pera M, May FE, Westley BR,
Martinez A and Morales L: Trefoil factor family peptide 3 prevents
the development and promotes healing of ischemia-reperfusion injury
in weanling rats. J Pediatr Surg. 39:1693–1700. 2004. View Article : Google Scholar
|
|
25
|
Serwin NM, Wisniewska M, Jesionowska A,
Skwirczyńska E, Marcinowska Z and Dołęgowska B: Serum levels of 12
renal function and injury markers in patients with
glomerulonephritis. Pol Arch Med Wewn. 126:483–493. 2016.
|
|
26
|
Schulze U, Hampel U, Sel S, Goecke TW,
Thäle V, Garreis F and Paulsen F: Fresh and cryopreserved amniotic
membrane secrete the trefoil factor family peptide 3 that is well
known to promote wound healing. Histochem Cell Biol. 138:243–250.
2012. View Article : Google Scholar
|
|
27
|
Taupin DR, Kinoshita K and Podolsky DK:
Intestinal trefoil factor confers colonic epithelial resistance to
apoptosis. Proc Natl Acad Sci USA. 97:799–804. 2000. View Article : Google Scholar
|
|
28
|
Kinoshita K, Taupin DR, Itoh H and
Podolsky DK: Distinct pathways of cell migration and antiapoptotic
response to epithelial injury: Structure-function analysis of human
intestinal trefoil factor. Mol Cell Biol. 20:4680–4690. 2000.
View Article : Google Scholar
|
|
29
|
Li XL, Zhou J, Chen ZR and Chng WJ: P53
mutations in colorectal cancer-molecular pathogenesis and
pharmacological reactivation. World J Gastroenterol. 21:84–93.
2015. View Article : Google Scholar
|
|
30
|
Manne U, Myers RB, Moron C, Poczatek RB,
Dillard S, Weiss H, Brown D, Srivastava S and Grizzle WE:
Prognostic significance of bcl-2 expression and p53 nuclear
accumulation in colorectal adenocarcinoma. Int J Cancer.
74:346–358. 1997. View Article : Google Scholar
|
|
31
|
Busch M, Klein S, Große-Kreul J, Scheiner
O, Metz K, Stephan H and Dünker N: P53, miR-34a and EMP1-newly
identified targets of TFF3 signaling in Y79 retinoblastoma cells.
Int J Mol Sci. 20:41292019. View Article : Google Scholar
|
|
32
|
Goswami CP and Nakshatri H: PROGgeneV2:
Enhancements on the existing database. BMC Cancer. 14:9702014.
View Article : Google Scholar
|
|
33
|
Morito K, Nakamura J, Kitajima Y, Kai K,
Tanaka T, Kubo H, Miyake S and Noshiro H: The value of trefoil
factor 3 expression in predicting the longterm outcome and early
recurrence of colorectal cancer. Int J Oncol. 46:563–568. 2015.
View Article : Google Scholar
|
|
34
|
Scholven J, Taras D, Sharbati S, Schön J,
Gabler C, Huber O, zum Büschenfelde DM, Blin N and Einspanier R:
Intestinal expression of TFF and related genes during postnatal
development in a piglet probiotic trial. Cell Physiol Biochem.
23:143–156. 2009. View Article : Google Scholar
|
